NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trials
We’ve closed a $435M Series C led by Founders Fund alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others.
We’ve closed a $435M Series C led by Founders Fund alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. We are bringing our first aging reprogramming medicine to human clinical trials next year. The accelerated timeline to trial is driven by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells. Reprogramming medicines NewLimit’s medicines are designed to restore youthful function…
saved by
related reading
- Bottlenecks of Aging - Amaranth Foundationamaranth.foundation
- A primer on the current state of longevity researchowlposting.com
- What the Aging Field Needs - Celine Haliouacelinehh.com
- World-first: therapy to make cells young again trialled in a personnature.com
- What we wish we knew entering the aging fieldlibrariesforthefuture.bio
- Nintil - Aging is already solved in vitro. What comes next?nintil.com
- age1’s 2024 wishlist for new companies to unlock healthy longevity for alllibrariesforthefuture.bio
- Anti-Aging: State of the Art — LessWronglesswrong.com
- Gap Mapgap-map.org
- Meet Altos Labs, Silicon Valley's latest wild bet on living forever | MIT Technology Reviewtechnologyreview.com
- Longevity FAQ - Laura Demingldeming.com
- Sam Altman invested $180 million into a company trying to delay death | MIT Technology Reviewtechnologyreview.com